Manulife Investment Management III Institutional ICAV (the ICAV)

An open-ended Irish collective asset management vehicle which is constituted as an umbrella fund with segregated liability between Funds and with variable capital and authorised under the European Communities (Undertakings for Collective Investment in Transferable Securities) Regulations, 2011 (as amended).

UK COUNTRY SUPPLEMENT

ADDITIONAL INFORMATION FOR INVESTORS IN THE UNITED KINGDOM

09 September 2026

This supplement contains information specific to investors in the United Kingdom regarding the ICAV. It forms part of and must be read in conjunction with the prospectus of the ICAV dated 27 November 2025 as amended and its supplements (the Prospectus) and KIID. It contains information for prospective investors and Shareholders in the United Kingdom (the UK). The product reference number for the ICAV, issued by the UK's Financial Conduct Authority (the FCA), is 1063259.

All capitalised terms used herein shall have the same meaning in this supplement as in the Prospectus, unless otherwise indicated.

The ICAV and the Funds are domiciled in Ireland and are authorised by the Central Bank of Ireland. The ICAV is managed by Manulife Investment Management (Ireland) Limited (the **Management Company**) which is domiciled in Ireland and authorised by the Central Bank of Ireland. The ICAV and the following Funds are recognised in the UK under the Overseas Funds Regime (which is a scheme recognised under s271A of the UK Financial Services and Markets Act 2000 (**FSMA**) but it is not a UK authorised fund.

Fund	**FCA product reference number**	**UK OFR Share Class**
Manulife India Bond Fund	**1063260**	All share classes

Shares in the above Funds may be promoted to the UK public by persons authorised to carry on investment business in the UK and will not be subject to restrictions contained in Section 238 of FSMA, as amended. Where the Management Company intends to communicate a financial promotion relating to the ICAV, the financial promotion will need to be approved unless the financial promotion benefits from an exemption in The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (**FPO**). The Prospectus (including this UK country supplement) can be made available to UK domiciled Shareholders in reliance on Article 29 FPO (Communications required or authorised by enactments) as it is a document required by local Irish law which is not prescribed under FSMA.

UK investors will not have the right, provided under Section 15 (Cancellation) of the Conduct of Business Sourcebook published by the FCA as part of its Handbook of Rules and Guidance (the **FCA Rules**), to cancel any investment agreement entered into with the ICAV.

Any individual who is in any doubt about the investment to which the Prospectus relates should consult an authorised person specialising in advising on investments of this kind, such as a financial adviser.

This product is based overseas and is not subject to UK sustainable investment labelling and disclosure requirements.

1 Facilities Agent in the United Kingdom

The Management Company (with the agreement of the ICAV) has appointed Manulife Investment Management (Europe) Limited, having its registered offices at 4th Floor, One Strand, London WC2N 5HR (the **Facilities Agent**) to maintain the facilities required of the operator of a recognised scheme pursuant to the rules contained in the Collective Investment Schemes Sourcebook published by the FCA as part of the FCA Rules. Such facilities will be found on the website www.manulifeim.com or located at Manulife Investment Management (Europe) Limited.

Any fees and expenses payable to the Facilities Agent shall be agreed at normal commercial rates.

2 Complaints and Compensation

Complaints about the operation of the ICAV, the Management Company or the Depositary may be submitted at the address of the Facilities Agent above. The complainant should provide a description of the facts, details of the complaint itself, their name and contact details, and enclose all relevant supporting documentation.

UK investors should be aware that if they invest in the ICAV, they may not be able to refer a complaint against the Management Company or the Depositary to the UK's Financial Ombudsman Service. Any claims for losses relating to the Management Company or the Depositary will not be covered by the Financial Services Compensation Scheme in the event that either person should become unable to meet its liabilities to investors.

UK investors will also not have a right to access a compensation scheme in Ireland in the event that either the Management Company or the Depositary, where applicable, should be unable to meet its liabilities to investors.

However, where a complaint has been handled by the Management Company and the UK investor is not satisfied with the outcome, a UK investor may, subject to meeting certain eligibility requirements, be able to raise a complaint with Financial Services and Pensions Ombudsman in the Republic of Ireland by writing to info@fspo.ie.

Further information can be found on the independent complaints resolution process can be obtained at www.fspo.ie. There is no cost for registering a complaint with the Financial Services and Pensions Ombudsman, who can direct a financial service provider to pay compensation to a complainant to a maximum value of EUR 500,000. Such directions arising from formal complaints are legally binding.

Complaints about the Facilities Agent can be made to the Financial Ombudsman Service, Exchange Tower, London E14 9SR. Further information can be found at www.financial-ombudsman.org.uk.

3 Additional Disclosures Required in the UK

3.1 A UK investor is not liable to make any further payment after they have paid the price of their Shares and no further liability can be imposed on them in respect of the Shares which they hold. Save as provided in the preceding sentence, UK investors are not liable for the debts of the ICAV.

3.2 The assets of a Fund belong exclusively to that Fund and shall not be used to discharge directly or indirectly the liabilities of, or claims against, any other person or body, including the ICAV, or any other Fund, and shall not be available for any such purpose.

3.3 The attention of UK investors is drawn to the relevant KIID, where information on past performance of the relevant Fund is available. Alternatively, past performance data can be made available on request.

3.4 No Funds have any interest, nor is it intended that they will have any interest, in any immovable or movable property for the direct pursuit of the ICAV's business.

3.5 Dealing in the Funds is on a forward price basis i.e. at the subscription or redemption price, as relevant, at the next valuation point following receipt of a fully completed and signed Application Form or redemption form. The Funds are single priced (which means there must be only a single price for any Share as determined from time to time by reference to a particular valuation point). The valuation point is outlined in the relevant supplement relating to each Fund.

3.6 Upon request, investors will be provided with a summary of the main terms of each contract of service between the ICAV and the Directors.

3.7 An exchange of Shares in one Fund for Shares in any other Fund is treated as a redemption and sale and will, for persons subject to United Kingdom taxation, be a realisation for the purposes of capital gains taxation.

3.8 Up-to-date information regarding (i) the duties and any conflicts of interest that may arise between the Depositary and the ICAV, the Shareholders, and the Management Company; (ii) a description of any safekeeping functions delegated by the depositary and any conflicts of interest that may arise from such delegation; and (iii) and a list showing the identity of each delegate and sub-delegate of the Depositary, will be made available to investors on request from the Administrator.

3.9 **Incorporation and Share Capital**

The ICAV was incorporated and registered in Ireland as an umbrella Irish collective asset-management vehicle with segregated liability between Funds pursuant to Part 2, Chapter 1 of the ICAV Act on 24 September 2025 with registered number C567473. The authorised share capital of the ICAV is 1,000,000,000,000,000 unclassified participating shares of no par value. The minimum issued share capital of the ICAV is 2 shares of no par value. The maximum issued share capital of the ICAV is 1,000,000,000,000,000 unclassified participating shares of no par value. The register of Shareholders can be inspected by Shareholders at the address of the Facilities Agent outlined above.

3.10 **Documents available for inspection**

Copies of the following documents may be obtained from the ICAV and inspected at the registered office of the ICAV during usual business hours on weekdays, except Saturdays and public holidays:

1. the Instrument of Incorporation of the ICAV (and any amendments);
2. the latest Prospectus (as amended and supplemented to) and the Supplements;
3. the key investor information document;
4. when available, the latest annual and half yearly reports.

3.11 **Notification of Prices of units in the scheme**

The Net Asset Value per Share of each Class of Shares in each Sub-Fund will be available from the office of the Administrator and from the office of the Facilities Agent and on www.manulifeim.com and such other website as disclosed in the relevant Supplement and such other place as the Directors may decide from time to time and as notified to the Shareholders in advance

3.12 **Redemption of shares**

Requests for the redemption of Shares should be made to the ICAV (via the Administrator) and may be made in writing, by facsimile or by any other means including electronic means agreed between the ICAV and the Administrator (provided that such means are in accordance with the requirements of the Central Bank) and must quote the relevant account number, the relevant Fund(s) and Class.

The Redemption Proceeds will be paid at the Shareholder's risk and expense by electronic transfer to an account in the name of the Shareholder in the currency of denomination of the relevant Class (or in such other currency as the Directors shall determine) by the Settlement Date,

Further information about the redemption of shares is set out in the Prospectus and fund supplement.

3.13 **Service of Notices**

The address for service on the ICAV of notices or other documents in the UK is the address of the Facilities Agent outlined above. Notices or other documents will be served on Shareholders in accordance with the provisions of the Constitution, which is available for inspection at the address of the Facilities Agent outlined above.

3.14 **The Management Company**

The names of other collective investment schemes to which the Management Company provides fund management services from time to time, are available at the registered office of the Management Company and on the Central Bank of Ireland register at https://registers.centralbank.ie.

3.15 **Dilution**

It is not possible to predict accurately whether dilution is likely to occur.

The Company may apply either a dilution levy or a swing pricing methodology on the subscription for and/or redemption of Shares in a Fund in order to reduce the risk of dilution on the existing or remaining Shareholders in the relevant Fund. The anti-dilution methodology chosen for each Fund, if any, will be determined by the appropriateness to the investment strategy or anticipated investor profile of that Fund and will be described in the relevant Supplement.

3.16 **Promotional payments**

Classes of Shares made available to UK investors will not bear promotional payments for the acquisition or promotion of Shares made to any person other than the Management Company.

The Directors of the ICAV, whose names appear under the heading "Directors of the ICAV" in the Prospectus are the persons responsible for the information contained in this UK country supplement and the Prospectus and accept responsibility accordingly. To the best of the knowledge and belief of the Directors (who have taken all reasonable care to ensure that such is the case) the information contained in this document is in accordance with the facts and does not omit anything likely to affect the import of the information.